000140856 001__ 140856
000140856 005__ 20240229112522.0
000140856 0247_ $$2doi$$a10.1158/1078-0432.CCR-18-1580
000140856 0247_ $$2pmid$$apmid:30274984
000140856 0247_ $$2ISSN$$a1078-0432
000140856 0247_ $$2ISSN$$a1557-3265
000140856 0247_ $$2altmetric$$aaltmetric:49133486
000140856 037__ $$aDKFZ-2018-01611
000140856 041__ $$aeng
000140856 082__ $$a610
000140856 1001_ $$0P:(DE-He78)82e0de3d5aa5330bb2470e74c48773ca$$aBerberich, Anne$$b0$$eFirst author$$udkfz
000140856 245__ $$aTargeting resistance against the MDM2 inhibitor RG7388 in glioblastoma cells by the MEK inhibitor trametinib.
000140856 260__ $$aPhiladelphia, Pa. [u.a.]$$bAACR$$c2019
000140856 3367_ $$2DRIVER$$aarticle
000140856 3367_ $$2DataCite$$aOutput Types/Journal article
000140856 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1655298651_9353
000140856 3367_ $$2BibTeX$$aARTICLE
000140856 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000140856 3367_ $$00$$2EndNote$$aJournal Article
000140856 520__ $$aResistance is an obstacle of glioma therapy. Despite targeted interventions, tumors harbor primary resistance or become resistant over short course of treatment. This study examined the mouse double minute 2 (MDM2) inhibitor RG7388 together with radiotherapy and analyzed strategies to overcome acquired MDM2 inhibitor resistance in glioblastoma.Effects of RG7388 and radiotherapy were analyzed in p53 wild-type glioblastoma cell lines and glioma-initiating cells. RG7388 resistant cells were generated by increasing RG7388 doses over three months. Regulated pathways were investigated by microarray, qRT-PCR and immunoblot analysis and specifically inhibited to evaluate rational salvage therapies at RG7388 resistance. Effects of RG7388 and trametinib treatment were challenged in an orthotopical mouse model with RG7388 resistant U87MG glioblastoma cells.MDM2 inhibition required functional p53 and showed synergistic activity with radiotherapy in first-line treatment. Long-term exposure to RG7388 induced resistance by activation of the extracellular signal-regulated kinases 1/2 (ERK1/2) - insulin growth factor binding protein 1 (IGFBP1) signaling cascade, which was specifically overcome by ERK1/2 pathway inhibition with trametinib and knockdown of IGFBP1. Combining trametinib with continued RG7388 treatment enhanced anti-tumor effects at RG7388 resistance in vitro and in vivo.These data provide a rationale for combining RG7388 and radiotherapy as first-line therapy with a specific relevance for tumors insensitive to alkylating standard chemotherapy and for the addition of trametinib to continued RG7388 treatment as salvage therapy after acquired resistance against RG7388 for clinical practice.
000140856 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000140856 588__ $$aDataset connected to CrossRef, PubMed,
000140856 7001_ $$0P:(DE-He78)5c2c9cbe6ce72553684d82d94aebdadd$$aKessler, Tobias$$b1
000140856 7001_ $$0P:(DE-He78)b759df221730b38264f533848f4bed4a$$aThome, Carina$$b2
000140856 7001_ $$0P:(DE-He78)f2efee17b6ca2f790176a2c036912536$$aPusch, Stefan$$b3
000140856 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b4
000140856 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b5
000140856 7001_ $$0P:(DE-He78)19ad2213f94e3900fa9a1b02f36b965a$$aOezen, Iris$$b6
000140856 7001_ $$0P:(DE-He78)150ba0b357f126058b563bcbfd6d43dd$$aSchmitt, Lara-Marie$$b7
000140856 7001_ $$0P:(DE-He78)def97b764dd6a3ca9aca3564f3c8437e$$aCiprut, Sara$$b8
000140856 7001_ $$0P:(DE-He78)f22b88c550ade8d906f161dde4fadd00$$aHucke, Nanina$$b9
000140856 7001_ $$0P:(DE-He78)4a2920bbf698256b49daaed4bcbd263c$$aRübmann, Petra$$b10
000140856 7001_ $$0P:(DE-He78)0a8e3638e3c0deb4e5e49c72286a5b83$$aFischer, Manuel$$b11
000140856 7001_ $$0P:(DE-He78)71cda0dea83ffa671c1d3b2f6e847ead$$aLemke, Dieter$$b12
000140856 7001_ $$0P:(DE-He78)5ba5b48bd126214d9cb66291fa4ae303$$aBreckwoldt, Michael$$b13
000140856 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b14
000140856 7001_ $$aBendszus, Martin$$b15
000140856 7001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b16
000140856 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b17$$eLast author
000140856 773__ $$0PERI:(DE-600)2036787-9$$a10.1158/1078-0432.CCR-18-1580$$gp. clincanres.1580.2018 -$$n1$$p253-265$$tClinical cancer research$$v25$$x1557-3265$$y2019
000140856 909CO $$ooai:inrepo02.dkfz.de:140856$$pVDB
000140856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)82e0de3d5aa5330bb2470e74c48773ca$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000140856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5c2c9cbe6ce72553684d82d94aebdadd$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000140856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b759df221730b38264f533848f4bed4a$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000140856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f2efee17b6ca2f790176a2c036912536$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000140856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000140856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000140856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19ad2213f94e3900fa9a1b02f36b965a$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000140856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)150ba0b357f126058b563bcbfd6d43dd$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000140856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)def97b764dd6a3ca9aca3564f3c8437e$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000140856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f22b88c550ade8d906f161dde4fadd00$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000140856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4a2920bbf698256b49daaed4bcbd263c$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000140856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0a8e3638e3c0deb4e5e49c72286a5b83$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000140856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)71cda0dea83ffa671c1d3b2f6e847ead$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000140856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ba5b48bd126214d9cb66291fa4ae303$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000140856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000140856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000140856 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000140856 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000140856 9141_ $$y2019
000140856 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN CANCER RES : 2017
000140856 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000140856 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000140856 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000140856 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000140856 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000140856 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000140856 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000140856 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000140856 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000140856 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bCLIN CANCER RES : 2017
000140856 9201_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x0
000140856 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000140856 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x2
000140856 9201_ $$0I:(DE-He78)D170-20160331$$kD170$$lNeuroimmunologie und Hirntumorimmunologie$$x3
000140856 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x4
000140856 980__ $$ajournal
000140856 980__ $$aVDB
000140856 980__ $$aI:(DE-He78)B320-20160331
000140856 980__ $$aI:(DE-He78)C060-20160331
000140856 980__ $$aI:(DE-He78)B300-20160331
000140856 980__ $$aI:(DE-He78)D170-20160331
000140856 980__ $$aI:(DE-He78)L101-20160331
000140856 980__ $$aUNRESTRICTED